|Common Name: Undecylenoyl Phenylalanine|
|INCI: Undecylenoyl Phenylalanine|
|Source: Amino Acids|
kligman ingredient evaluation
|Penetration: Under analysis|
|Biochemical Mechanism: Under analysis|
|Level of Evidence: Under analysis|
Undecylenoyl Phenylalanine is an amino acid derivative studied as a skin brightener. It's main action is to inhibit the activity of alpha melanocyte stimulating hormones (a-MSH).
Studies tell us to • Look for Undecylenoyl Phenylalanine in concentrations of .5% - 2.5% • Best results are obtained if combined with 5% Niacinamide and used twice daily (in conjunction with a suncreen) • While potent, it's a little slow: look for best results within 1-3 months
*Preliminary Lab Notes*Sign up below to get notified when we release the complete analysis! https://pubchem.ncbi.nlm.nih.gov/compound/10308702
What is Undecylenoyl Phenylalanine and how it works?
Undecylenoyl Phenylalanine is a compound that includes amino acids and lipid residue, used in cosmetics and personal care products, specifically whitening formulas, to prevent skin cells from producing melanin pigmentation. Undecylenoyl Phenylalanine inhibits melanotropin, a melanin stimulator found in the skin. Melanotropin controls tyrosinase activity (tyrosinase being an essential enzyme in the production of melanin), melanin (eumalanin) synthesis and melanosome; therefore, by preventing the production of melanotropin, the pigmentation process is reduced or halted.
A study was done to evaluate the efficacy and safety of a preparation containing undecylenoyl phenylalanine 2% in the topical treatment of solar lentigines. In total, 36 patients with solar lentigines of the hands were randomly assigned to apply the active preparation on one side and the vehicle alone on the other side, twice daily for 12 weeks. Undecylenoyl phenylalanine 2% is a novel depigmenting agent, which possibly acts as an alpha-melanocyte-stimulating hormone antagonist, thus inhibiting melaninogenesis. It achieved a significant lightening of the lesions with minimal side-effects. Most patients were satisfied with the improvement.
Clin Exp Dermatol. 2010 Jul;35(5):473-6. doi: 10.1111/j.1365-2230.2009.03605.x. Epub 2009 Oct 23.